Profilo
Sally Dewhurst is currently a Director at Grey Wolf Therapeutics Ltd., a Principal at Oxford Science Enterprises PLC, and a Board Member at Alethiomics Ltd. Previously, she was a Board Observer at DJS Antibodies Ltd. Ms. Dewhurst graduated from the University of Durham in 2011.
Posizioni attive di Sally Dewhurst
| Società | Posizione | Inizio |
|---|---|---|
Grey Wolf Therapeutics Ltd.
Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops next generation immuno-oncology drugs | Direttore/Membro del Consiglio | 24/01/2023 |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises invests in companies located in the United Kingdom. The firm targets companies operating in the fields of health tech, deep tech, and life sciences sectors. It provides financing for seed and early stage capital requirements with an investment size of GBP 0.1 – 10 million. | Investitore di Private Equity | 01/07/2023 |
Alethiomics Ltd.
Alethiomics Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Direttore/Membro del Consiglio | 01/11/2022 |
Precedenti posizioni note di Sally Dewhurst
| Società | Posizione | Fine |
|---|---|---|
DJS Antibodies Ltd.
DJS Antibodies Ltd. BiotechnologyHealth Technology Operates as a biotechnology company | Corporate Officer/Principal | 01/10/2022 |
Formazione di Sally Dewhurst
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
University of Durham
University of Durham Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises invests in companies located in the United Kingdom. The firm targets companies operating in the fields of health tech, deep tech, and life sciences sectors. It provides financing for seed and early stage capital requirements with an investment size of GBP 0.1 – 10 million. | Finance |
DJS Antibodies Ltd.
DJS Antibodies Ltd. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Grey Wolf Therapeutics Ltd.
Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops next generation immuno-oncology drugs | Health Technology |
Alethiomics Ltd.
Alethiomics Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Commercial Services |
















